AtaiBeckley (ATAI) to Start Phase 3 Study in Depression Following Positive FDA Meeting
AtaiBeckley Inc. (NASDAQ:ATAI) is one of the The best budget stocks to buy for under $5.. On March 3, AtaiBeckley announced a successful end-of-Phase 2 meeting with the FDA regarding BPL-003, a proprietary intranasal formulation of mebufotenine benzoate for treatment-resistant depression/TRD. The FDA indicated its support for the proposed Phase 3 program, providing constructive comments…